Share Name Share Symbol Market Type Share ISIN Share Description
Ip Group Plc LSE:IPO London Ordinary Share GB00B128J450 ORD 2P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.40 -0.29% 136.60 1,897,227 16:29:58
Bid Price Offer Price High Price Low Price Open Price
136.40 136.80 137.20 136.00 137.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 186.10 17.47 7.8 1,451
Last Trade Time Trade Type Trade Size Trade Price Currency
17:17:35 O 3,302 136.399 GBX

Ip (IPO) Latest News

More Ip News
Ip Investors    Ip Takeover Rumours

Ip (IPO) Discussions and Chat

Ip Forums and Chat

Date Time Title Posts
24/9/202113:38IP Group PLC1,526
02/9/202119:51ONT future steps.3
23/12/202009:51IP Group - commercialising university technology.971
11/10/201207:43::: The DIRECT LINE IPO :::83
08/11/201007:59IP 2 IPO, digging up value, from the boffins.213

Add a New Thread

Ip (IPO) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Ip trades in real-time

Ip (IPO) Top Chat Posts

Ip Daily Update: Ip Group Plc is listed in the General Financial sector of the London Stock Exchange with ticker IPO. The last closing price for Ip was 137p.
Ip Group Plc has a 4 week average price of 125p and a 12 week average price of 110.20p.
The 1 year high share price is 156.20p while the 1 year low share price is currently 74p.
There are currently 1,062,353,734 shares in issue and the average daily traded volume is 3,219,784 shares. The market capitalisation of Ip Group Plc is £1,451,175,200.64.
edwardt: lets hope we have more of a darktrace than a deliveroo on our hands. my guess is this will be hugely oversubscribed and ont via their very well paid bankers will 'feed the ducks' with extra stock into a strongly rising share price post ipo. lets see- this is why this hobby is such fun!
wba1: I am surprised at the focus of posts on the science/tech benefits of the Oracle announcement. It seems obvious that the short term benefit (and reason for the timing) is that it will greatly benefit the IPO with potential US investors. Equally obviously Oracle would only be investing at this point (and so publicly) if they believe the company and share price will grow significantly following IPO. No doubt there are long term benefits in ONT/Oracle collaboration, but the simple benefits to the IPO are most important for the next month.
masurenguy: IP Group plc - Portfolio company IP Group plc (LSE: IPO) notes that portfolio company Oxford Nanopore Technologies Limited ("Oxford Nanopore" or "the Company"), the Company behind a new generation of nanopore-based sensing technology, whose products enable the real-time, high-performance, scalable analysis of DNA and RNA, has confirmed its intention to proceed with an initial public offering as well as the signing of a strategic memorandum of understanding and cornerstone investment agreement with Oracle Corporation. Oxford Nanopore intends to apply for admission of its Shares to the standard listing segment of the Official List of the FCA and to trading on the London Stock Exchange's main market for listed securities. The final offer price in respect of the Offer (the "Offer Price") will be determined following a book-building process, with Admission currently expected to occur in early October 2021. IP Group, which was a founding shareholder in Oxford Nanopore in 2005, has a 14.4% undiluted beneficial stake in the Company, which was valued at £359 million as at 30 June 2021. Oxford Nanopore noted that the Offer would comprise a primary offer of new Shares to be issued by the Company, which is expected to raise gross proceeds of approximately £300 million, and a secondary offer of existing Shares to be sold by certain existing shareholders. In addition, Oxford Nanopore noted that it has recently entered into a memorandum of understanding with Oracle, whereby the two companies will explore collaboratively a number of potential new solutions to address opportunities in the applied and clinical markets, and related go-to-market strategies. The collaboration is intended to draw on Oxford Nanopore's strengths in sequencing and genetic analysis, together with Oracle's strengths in database and cloud technologies. Separately, the Company and a vehicle controlled by Oracle have entered into a cornerstone investment agreement, pursuant to which such entity has irrevocably agreed, subject to certain customary conditions, to subscribe for GBP150 million of New Shares at the Offer Price. The Company is targeting a free float of at least 25% of the Company's issued share capital at Admission. Alan Aubrey, Chief Executive of IP Group , said: "IP Group has been with Oxford Nanopore from day one and has actively supported the Company in a number of ways since then in addition to providing capital. We are delighted to see Oxford Nanopore take the next steps on its journey."
pierre oreilly: Alan was appointed as a Non-Executive Director in March 2009. Alan has informed the Board that should any potential IPO occur, he intends to retire from the Board and his position as chair of the audit and risk committee at the date of such IPO. .................... The above from the nano float documents. I think we can assume from that (might be wrong of course) that ipo are liquidating most of their holding in the float. Elsewhere, it's interesting that ipo was the initial seed capital investor in nano enabling it to launch.
wetpantz: The IPO announcement was expected and held few surprises. The unusual share price volatility this week makes me wonder if there's a big player trying to shake out some longer term holders.
wetpantz: I'm a bit puzzled by the size and volume of today's share price move. Was no secret that the ONT float would be announced. I suspect that would-be investors in the flotation haven't been able to get the allocation they were hoping for and are looking for other ways to get ONT exposure. The genomics sector is red hot right now so ONT share price likely to rocket post-IPO as thematic ETFs etc buy in. Hold on for the ride.
bamboo2: Link to ONT accounts to 31/12/2020 in header. Outlook, LSRT part of the co growing 80%+ in first six months of 2021. Confirmation that Management will get up to 6.5% of the co in performance related bonus. Also LAT shares to protect against a takeover in the first three years. This has all been agreed in advance with long term investors. Since the figures are now in the public domain, earlier than the latest required filing date, could this mean the IPO will come sooner than I suggested? On the technical side, some of the future developments in product performance look stunning. Watch out Illumina. edit added, since so much has already been agreed with long term investors, does this point towards IPO management having inside info that could affect the share price? If so, I doubt that we will get any buy backs until ONT's flotation plan sees the light of day.
pierre oreilly: 16,000,000,000 x 0.145 = 2,320,000,000 / 1,062,350,000 = 2.18 So by my calcs. nano at £16bn works out at £2.18 per ipo share. Current price = £1.19p/share So everything else except nano at 16bn is worth minus £1 / share. At the mid range float price mentioned (4-7bn, being £5.5bn), nano is worth 2.18*5.5/16, which is 75p/share, valuing everything else except nano at 45p/share. IPO have hinted they may return some of the cash raised to shareholders. If they liquidate half their stake i.e. 37.5p, and keep half invested for future growth, and return some of the cash raised, we'd get a cash return between 0 and 37.5p. Whatever, on any basis, the price of nano isn't yet reflected by a long margin in ipo's price
bamboo2: Good news, particularly about the buyback. Webinar at 10.15am today. These are normally worthwhile, with a live Q&A. If you want to submit a question during this time, it is worth preparing in advance what you want to say in another text editor, then paste it to Zoom's small text box. =============================================================== IP Group plc - AGM statement IP Group plc (LSE: IPO) ("IP Group" or "the Company" or "the Group"), the developer of intellectual property-based businesses, issues the following statement ahead of its Annual General Meeting, which is a closed meeting taking place at 10am today and which will be followed by a virtual event for shareholders at 10.15am . All shareholders are invited to join the virtual event at 10.15am while we politely remind shareholders that the 2021 AGM is a closed meeting with the minimum attendance required to form a quorum (being two shareholders). No other shareholders will be permitted to physically attend the meeting in accordance with the UK Government's current COVID-19 guidelines and to safeguard shareholders, employees and the wider community. No material new information will be released by the Company during the virtual event. This statement provides an update on the Group's progress for the period since 31 December 2020. Business and operational update During the year to date, IP Group has seen a continuation of the positive progress made by many of its portfolio companies during 2020. A summary of significant portfolio events is set out below. The Group remains well financed and, as at 31 May 2021, had gross cash and deposits of GBP228.7 million (FY20: GBP270.3 million) and net cash (gross cash and deposits less EIB debt) of GBP169.1 million (FY20: GBP203.0 million) Shareholder returns and inaugural dividend As described in the 2020 full year results release, the Board considers that IP Group shareholder returns will continue to be driven primarily by long-term capital appreciation. The Board also considers that the business model has reached a sufficient stage of maturity that a modest but growing dividend should form a small part of the overall shareholder value proposition. Consistent with this approach, and assuming approval of the relevant resolutions at the Group's AGM later today, the Group will pay its inaugural dividend of one pence per ordinary share on 16(th) June. GBP10.1 million of the dividend will be settled in cash and GBP0.5m via the issue of new ordinary shares under the Group's scrip programme. The Board also anticipates receiving shareholder approval to renew the authority to purchase up to 10% of the ordinary shares in issue from the date of grant of the authority to the date of the Annual General Meeting in 2022. Such purchases will only be made at a discount to the prevailing Hard NAV per share. Any decision to repurchase shares would be undertaken in light of other potential capital investment opportunities for the benefit of stakeholders and remains subject to regular review. Portfolio update The Group's portfolio includes holdings in 40 'focus' companies across life sciences, deeptech and cleantech, representing over 84% of the portfolio value at 31 December 2020. In the year to date, the Group has invested over GBP50 million in 32 portfolio companies and made cash realisations of GBP16 million. The Directors anticipate that cash realisations in the first half of the year will exceed GBP80 million following the completion of certain portfolio transactions described below. Management is currently undertaking its regular fair value assessment exercise as part of its half-yearly results processes and looks forward to updating shareholders in August. Significant developments in the Group's portfolio since 31 December 2020 include: -- NeoGenomics, Inc agreed to acquire Inivata Ltd, a leader in liquid biopsy, resulting in IP Group receiving approximately GBP65 million* ($91 million) in cash and an anticipated increase in the Group's net asset value of approximately GBP28 million. -- Waveoptics Ltd was sold to Snap Inc, in one of Europe's largest deeptech exits, as announced on 17 May. Following completion, IP Group has recorded a fair value increase of approximately GBP20 million. -- Oxford Nanopore Technologies Ltd raised GBP202 million in new capital including GBP125 million from new investors Temasek, Wellington Management, M&G Investments and Nikon with existing shareholders investing GBP77 million. Following completion of the round, IP Group has a 14.5% undiluted beneficial stake in Oxford Nanopore, valued at GBP359 million. Oxford Nanopore announced in March that it had started the process of preparing for a potential Initial Public Offering. -- Kuur Therapeutics Ltd was acquired by Athenex, Inc. for a total potential consideration of $185 million with IP Group eligible to receive GBP30 million* ($42 million) in Athenex stock and up to a further GBP51 million* ($72 million) in milestone payments in cash or stock. The Directors anticipate that the transaction will result in an increase in the Group's net asset value of approximately GBP26 million*. -- Centessa Pharmaceuticals plc announced that its Nasdaq IPO had closed on 2 June 2021 and its American Depositary Shares were now trading under the symbol 'CNTA'. IP Group had previously announced that portfolio company Apcintex Ltd had been acquired by Centessa. Based on the IPO price of $20 per share, the value of the Group's 2.8% holding in Centessa was GBP36 million* ($51 million) , resulting in an increase in the Group's net asset value of GBP15 million. Centessa noted that gross proceeds from the offering totalled $379.5 million. -- Diurnal Group plc announced on May 28 that the European Commission (EC) had approved the marketing authorisation for Efmody(R) (hydrocortisone modified-release hard capsules, development name Chronocort(R) ) as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). This decision by the EC follows the positive opinion issued by the European Medicines Agency (EMA) in March 2021. First commercial launch is anticipated in Q3 2021. -- Pulmocide Ltd completed a $92 million Series C financing. Following completion and the investment of the first tranche of GBP2.2 million, IP Group will have a 14.4% undiluted beneficial stake in Pulmocide, which will be valued at GBP8.0 million.
bamboo2: FOR RELEASE ON 20 May 2021 IP Group plc Scrip Dividend Reference Price Further to the Company's Annual Results Release on 10 March 2021 and the 2021 AGM Notice which was published on 6 May 2021, the Company announces that the Scrip Reference Share Price for the 2020 Final Dividend, payable on 16 June 2021, is 118.6 pence. Defined terms in this announcement are as defined in the 2021 AGM Notice. The Scrip Reference Share Price is the price at which the Company's Ordinary Shares will be issued to shareholders who have elected to receive dividends in the form of newly issued, fully paid shares in the Company in lieu of cash through participation in the optional Scrip Dividend Scheme. The Scrip Reference Share Price is the average of the mid closing price of the Company's Ordinary Shares, as derived from the London Stock Exchange Daily Official List, for the five dealing days commencing on the relevant ex-dividend date (being 13, 14, 17, 18 and 19 May 2021). Any shareholder entitled to the 2020 Final Dividend who has not already completed a Scrip Dividend Mandate Form or a Dividend Election Input Message in CREST and is intending to do so, should refer to the Scrip Dividend Scheme Terms and Conditions contained within the 2021 AGM Notice which can be found at: hxxps://www.ipgroupplc.com/investor-relations/shareholder-information/agm . The final time and date for receipt of Scrip Dividend Mandates and Dividend Election Input Messages in CREST is 5:00pm on 28 May 2021.
Ip share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210925 16:55:57